Ciprofolxacin Injectable (Iv) Suppliers & Bulk Manufacturers
Available Forms: Injectable (IV)
Available Strengths: 200 mg/100 mL, 400 mg/200 mL
Reference Brands: Cipro(US & EU)
Category:
Antibiotics
Ciprofloxacin IV inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and leading to bacterial cell death. It provides rapid, broad-spectrum activity against severe infections such as sepsis and pneumonia. Benefits include high tissue penetration, quick onset, and effective treatment of serious bacterial infections in hospital settings.
Ciprofolxacin Injectable (IV) is available in Injectable (IV)
and strengths such as 200 mg/100 mL, 400 mg/200 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ciprofolxacin Injectable (IV) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ciprofolxacin Injectable (IV) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ciprofloxacin IV is approved in the EU and US for severe bacterial infections, including sepsis, pneumonia, and complicated urinary tract infections. In the EU, brands like Cipro are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for ciprofloxacin IV, ensuring adherence to European and US standards for safe, effective treatment of serious bacterial infections.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing